Pancreatic Cancer Research

ResearcherGuangxi Medical UniversityActive in the last 2 years

Yi Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5195-5294; OpenAlex author ID A5100753051. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 3

  1. MiR-766-3p Inhibit the Proliferation, Stemness, and Cell Cycle of Pancreatic Cancer Cells Through the MAPK/ERK Signaling Pathway. Co-author DOI 10.1002/mgg3.70049↗
  2. BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo. Co-author DOI 10.1007/s10620-018-5253-7↗
  3. Paeoniflorin inhibits human pancreatic cancer cell apoptosis via suppression of MMP-9 and ERK signaling. Co-author DOI 10.3892/ol.2016.4761↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yaqun Yu · 1 shared paper, 2024 · strength 0.21
  2. Zhipeng Quan · 1 shared paper, 2024 · strength 0.21
  3. Ruyi Xue · 1 shared paper, 2018 · strength 0.11
  4. Shuncai Zhang · 1 shared paper, 2018 · strength 0.11
  5. Jinxue Zhou · 1 shared paper, 2016 · strength 0.07
  6. Feng Han · 1 shared paper, 2016 · strength 0.07
  7. Nanmu Yang · 1 shared paper, 2016 · strength 0.07
  8. Tao Huang · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.